{
    "2021-09-24": [
        [
            {
                "time": "2021-09-24",
                "original_text": "研发投入超十亿 恒瑞医药一乳腺癌新药拟被纳入优先审评程序",
                "features": {
                    "keywords": [
                        "恒瑞医药",
                        "乳腺癌",
                        "新药",
                        "优先审评"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2021-09-24",
                "original_text": "晚间重要公告2021年9月24日星期五",
                "features": {
                    "keywords": [
                        "晚间公告",
                        "9月24日"
                    ],
                    "sentiment_score": 0.5,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [],
                    "causal_factor": "false",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2021-09-24",
                "original_text": "9月24日通威股份、恒瑞医药等8家公司公告出现利好",
                "features": {
                    "keywords": [
                        "恒瑞医药",
                        "利好",
                        "公告"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2021-09-24",
                "original_text": "恒瑞医药：获得美国FDA临床试验资格",
                "features": {
                    "keywords": [
                        "恒瑞医药",
                        "FDA",
                        "临床试验",
                        "资格"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2021-09-24",
                "original_text": "恒瑞医药（600276.SH）：马来酸吡咯替尼片拟纳入优先审评程序",
                "features": {
                    "keywords": [
                        "恒瑞医药",
                        "马来酸吡咯替尼片",
                        "优先审评"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2021-09-24",
                "original_text": "恒瑞医药：注射用SHR-A1904治疗晚期实体瘤临床研究计划获美国FDA临床试验资格",
                "features": {
                    "keywords": [
                        "恒瑞医药",
                        "SHR-A1904",
                        "FDA",
                        "临床试验"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2021-09-24",
                "original_text": "恒瑞医药（600276.SH）：注射用SHR-A1904获美国FDA临床试验资格",
                "features": {
                    "keywords": [
                        "恒瑞医药",
                        "SHR-A1904",
                        "FDA",
                        "临床试验"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2021-09-24",
                "original_text": "恒瑞医药：美国方面同意公司注射用SHR-A1904治疗晚期实体瘤的临床研究",
                "features": {
                    "keywords": [
                        "恒瑞医药",
                        "SHR-A1904",
                        "FDA",
                        "临床研究"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2021-09-24",
                "original_text": "恒瑞医药长期逻辑变了嗎？丨价值三人行",
                "features": {
                    "keywords": [
                        "恒瑞医药",
                        "长期逻辑",
                        "价值三人行"
                    ],
                    "sentiment_score": 0.5,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2021-09-23",
                "original_text": "A股融资融券日报：两融余额增加70.33亿元（9月23日）",
                "features": {
                    "keywords": [
                        "A股",
                        "融资融券",
                        "两融余额"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [],
                    "causal_factor": "false",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}